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Abstract: Morphine is the archetypal opioid analgesic. Because it is a short-acting opioid, its 
use has been limited to the management of acute pain. The development of extended-release 
formulations have resulted in the increased utilization of morphine in chronic pain conditions. 
This review documents the history of morphine use in pain treatment, and describes the metabo-
lism, pharmacodynamics, formulations, and efficacy of the currently available extended-release 
morphine medications.
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Introduction
Morphine was the first, and in many ways, the most important opioid used to treat 
acute and cancer pain. However, morphine is a short-acting medication, and the fre-
quency of administration necessary to maintain adequate blood levels made it difficult 
to use this agent in the chronic setting. It was not until morphine was available in a 
long-acting formulation that it became used for chronic, noncancer pain. With once 
or twice a day dosing, steady-state blood levels can be achieved, compliance can be 
improved, and patients can sleep through the night. There should also, theoretically, 
be less reinforcement of drug misuse behavior, although that has never been proven.
History
Opioids have been used for their euphoric and analgesic properties for thousands of 
years. Records show that around 3400 BC,1 the opium poppy was cultivated in lower 
Mesopotamia by the Sumerians, who referred to it as Hul Gil, the “joy plant”. Ancient 
records indicate that it was also used by the Assyrians, Babylonians, and Egyptians.2 
A German pharmacist, Frederick Wilhelm Adam Serturner, isolated morphine from 
opium in 1804. He accomplished this by boiling the poppy plant and precipitating 
crystals from the water using ammonia, yielding a water-insoluble crystal.3 After 
ingesting the crystals, Serturner discovered that the compound induced a dreamlike 
state. Thus, in 1817, he named the compound “morphium” after Morpheus, the Greek 
god of dreams.4 Joseph Louis Gay-Lussac coined the term “morphine” later as a result 
of a German-French translation.
Although Serturner is known as the scientist who first isolated morphine, it was 
not until 1925 that Robert Robinson deduced the empiric formula, and in 1952 it was 
synthesized in the laboratory by Marshal T Cates, Jr. Nonetheless, it is Serturner who Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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is now considered the “father of alkaloid chemistry”, and 
his discovery is said to have marked the beginning of the 
“modern era of narcotics”.5 Serturner’s early experiments 
proved that plants contain active substances that, on isola-
tion, carry the “therapeutic properties of the plant”; it is no 
surprise, then, that the isolation of morphine, the first of such 
“natural products” was a “seminal event in the development 
of pharmacology as an independent discipline”.3
Alkaloids are natural occurring, nitrogen-containing 
bases found in plants. Morphine is only one of 24 such 
alkaloids found within the resin of the opium poppy plant 
(Papaver somniferum), and comprises approximately 10% 
of the total opium extract.
Opioid receptors
The term “opioid” is now used broadly to describe any 
compound that exerts activity at an opioid receptor. The 
opioid receptors were first discovered in 1972,6 and the first 
endogenous opioid (enkephalin) was subsequently discov-
ered in 1975.7 The different opioid receptors include Mu-1, 
Mu-2, kappa, and delta. Mu receptors are found primarily 
in the brainstem and medial thalamus. Activation of these 
receptors can result in supraspinal analgesia, respiratory 
depression, euphoria, sedation, decreased gastrointesti-
nal (GI) motility, and physical dependence. The subtype 
Mu-1 is mostly associated with analgesia, euphoria, and 
serenity, while Mu-2 is related to respiratory depression, 
pruritus, prolactin release, dependence, anorexia, and 
sedation. Kappa receptors are found in the limbic and 
other diencephalic areas, brainstem, and spinal cord, and 
are responsible for spinal analgesia, sedation, dyspnea, 
dependence, dysphoria, and respiratory depression. Delta 
receptors are located largely in the brain and their effects 
are not well studied. Currently, activation of delta recep-
tors is thought to be responsible for psychomimetic and 
dysphoric effects.8
These opioid receptors are G-linked proteins embedded 
in the cell membrane. When the opioid attaches to the recep-
tor, the receptor is activated, releasing a portion of the G 
protein, which diffuses within the cytoplasm until it reaches 
its target (either an enzyme or an ion channel). These targets 
alter protein phosphorylation via inhibition of cyclic AMP 
(cAMP), which acts as a second messenger within the cell, 
resulting in the activation of protein kinases (short-term 
effects) and gene transcription proteins and/or gene tran-
scription (long-term effects),9 as shown in Figure 1.
Opioid receptors located on the presynaptic terminals of 
nociceptive C fibers and A delta fibers, when activated by 
an opioid agonist, will indirectly inhibit voltage-dependent 
  calcium channels, thereby decreasing cAMP levels and 
blocking the release of pain neurotransmitters such as 
glutamate, substance P, and calcitonin gene-related pep-
tide from the nociceptive fibers, resulting in analgesia 
(Figure 2). Opioids and endogenous opioids also activate 
presynaptic receptors on gamma aminobutyric acid (GABA) 
neurons, which inhibit the release of GABA in the ven-
tral tegmental area10 (Figure 3). The inhibition of GABA 
allows dopaminergic neurons to fire more vigorously, and 
the extra dopamine in the nucleus accumbens is intensely 
pleasurable.11
Structure
The basic morphine compound in its raw form exists as a 
bitter, white crystalline compound that is water-insoluble. 
It is designated with the chemical formula C17 H 19 NO3. 
Pharmaceutical-grade morphine exists as a salt, typically in 
the form of morphine hydrochloride, morphine acetate, or 
morphine sulfate (Figure 4).
Pharmacodynamics
Morphine has very poor lipid solubility, undergoes rapid 
conjugation with glucuronic acid, ionizes at physiologic pH 
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and becomes highly protein-bound after oral administration. 
Thus, only 40%–50% of the originally administered oral dose 
reaches the central nervous system. It takes approximately 
30 minutes for the immediate-release morphine formulation 
to reach the central nervous system, and 90 minutes for the 
extended-release formulation.12 The elimination half-life of 
morphine approximates 120 minutes. Only about 40% of the 
administered dose reaches the central compartment because 
of first-pass effect (ie, metabolism in the gut wall and liver). 
Once absorbed, morphine is distributed to skeletal muscle, 
kidneys, liver, intestinal tract, lungs, spleen, and brain. 
Morphine also crosses the placental membrane and has been 
found in breast milk.
The nonalkalinized form of morphine crosses the blood-
brain barrier more readily than the alkalinized form. Alka-
linization of the blood increases the fraction of nonionized 
morphine, thereby enhancing delivery to the central nervous 
system.8 One scenario where this is not the case is respiratory 
acidosis. During respiratory acidosis, brain concentrations of 
morphine increase because of increased cerebral blood flow 
secondary to higher carbon dioxide tension, which facilitates 
delivery of the nonionized form through the blood-brain 
barrier.
Metabolism
Glucuronidation of morphine occurs immediately after it 
is absorbed into the serum at both hepatic and extrahepatic 
sites.13 Glucuronidation produces morphine-6 glucuronide 
(M6G) and morphine-3 glucuronide (M3G) in a ratio 
of 6:1.   Approximately 5% of morphine is metabolized 
into   normorphine by demethylation.8 Similar to the parent 
compound, M6G may provide additional analgesic effects.14 
However, M3G is thought to lead to hyperalgesia in high 
  concentrations.15 The first phase of morphine metabolism is 
carried out by the cytochrome P450 system and the second 
phase by the enzyme UGT2B7. The enzymes, CYP 3A4 and 
CYP2C8, are responsible for demethylation of morphine 
into normorphine.16 Morphine is also metabolized in small 
amounts to the drugs codeine and hydromorphone.8
Side effect profile
One of the most feared side effects of morphine is that of 
respiratory depression, with subsequent potential respira-
tory arrest.17 Direct respiratory depression is mediated by 
the effect of morphine on the nucleus accumbens in the 
  brainstem, resulting in a decreased response to arterial carbon 
dioxide tension and a shift of the oxygen response curve to 
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the right. Morphine also leads to decreased sympathetic tone, 
resulting in venous pooling and orthostatic hypotension. 
Effects on the GI and genitourinary systems include spasm 
of biliary smooth muscle, sphincter of Oddi spasm, decreased 
intestinal motility with constipation, direct stimulation of the 
chemotactic receptor trigger zone in the floor of the fourth 
ventricle resulting in nausea and vomiting, and spasm of 
the bladder trigone with urinary retention. Morphine is also 
associated with direct histamine release, which can lead 
to bronchospasm, hypertension, peripheral vasodilatation, 
flushing of the skin, and urticaria.8
Addiction, tolerance, dependence, 
and opioid hyperalgia
All opioids are associated with the risk of addiction, 
  tolerance, dependence, and hyperalgia. Because opioids 
increase   dopamine levels in the brain, they produce a 
pleasurable   sensation, which is felt to be addictive. These 
dopamine centers are also the site of action of the addictive 
actions of alcohol, nicotine, and cocaine.8 Benyamin et al2 
wrote that “Currently, statistics show that approximately 
90% of patients with chronic pain receive opioids, and 90% 
of patients presenting to an interventional pain management 
center are already on opioids”. McCleane and Smith9, in their 
review of opioids for persistent noncancer pain, describe that 
“with the increasing availability of modified strong opioid 
preparations, either in transdermal or oral formulations, 
and the increased advertising of their use by the pharma-
ceutical industry, there is an increased pressure to prescribe 
accompanied by an increased willingness to use opioids, 
particularly those that are classified as being strong”. This 
has led to a dramatic increase in opioid prescribing, includ-
ing extended-release morphine, with a concomitant increase 
in opioid poisonings and death. The benefit of analgesia, 
therefore, must always be balanced with the risk of addic-
tion and overdose.
Tolerance, ie, loss of analgesic potency, leads to increas-
ing dose requirements. The opioid receptors can become 
upregulated by continued exposure to the medication, or 
the enzymes controlling metabolism can be induced by 
prolonged exposure.2 Physical dependence is the develop-
ment of an opioid withdrawal syndrome when the opioid 
is no longer attached to the receptors, and, unlike common 
conceptions, is not related to addiction. Hyperalgia (or 
hyperalgesia) is defined as increased pain sensitivity in 
the setting of an increased opioid dose. Opioid metabolites 
such as M3G may be involved; other etiologies include 
loss of GABA neurons to apoptosis, N-methyl D-aspartate 
(NMDA) receptor agonism, and postsynaptic inhibition of 
spinal neurons.2
Sustained-release morphine
Morphine had a limited impact on medical science until the 
invention of the hypodermic needle by a Scottish   physician, 
Alexander Wood, sometime between 1840 and 1850.4 
The invention of the hypodermic needle escalated the use of 
morphine for control of pain, particularly during and after 
the American Civil War. The subsequent development of a 
commercially available oral form of morphine heralded the 
discipline of modern pain medicine as we now know it.
Major advances in the pharmacotherapy of chronic pain 
have led to the development of extended-release opioid 
delivery systems, thereby allowing less frequent dosing than 
the classic short-acting formulas. It is the patterns in serum 
drug levels that define the difference between short-acting 
opioids (SAO) and long-acting opioids (LAO); with SAOs, 
serum opioid levels rise rapidly following administration 
and then decline rapidly, while LAO administration allows 
for less fluctuation in serum opioid levels and an extended 
period within the therapeutic range.18 The assumption that 
plasma levels of opioids correspond to analgesia has led 
to the additional concept of minimum effective concentra-
tion, the plasma level of an opioid below which there is 
ineffective analgesia.
There are many proposed advantages of the long-acting 
formula compared with the short-acting formula. Several 
studies have suggested that modified-release opioids may 
result in fewer side effects than have been observed with 
short-acting opioids.19–21
The modified-release opioids have been preferred over 
the short-acting opioids because of the longer duration of 
action, which lessens the frequency and severity of end-
of-dose pain.22 Furthermore, it has been suggested that 
less frequent dosing leads to increased compliance and 
improved efficacy.23 Sustained analgesia and uninterrupted 
sleep are other potential advantages of the extended-release 
formulation compared with the short-acting variety. How-
ever, in a recent systematic review of long-acting versus 
short-acting opioids,24 Rauck noted that, while it was clear 
that long-acting opioids achieved more stable drug levels, 
there was no clear evidence from appropriately designed 
comparative trials to make a case for the use of one type of 
formulation over the other on the basis of clinical efficacy.
Several extended-release oral morphine   formulations are 
now commercially available. The dose intervals recommended 
for these formulations vary from 8 to 12 to 24 hours. The Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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most common formulations include   MSContin®, Oramorph®, 
Avinza®, and Kadian®. MSContin, Oramorph®, and Kadian® 
were originally developed for twice a day dosing, whereas 
Avinza® was developed for once-daily dosing. In this article, 
we will also briefly discuss Embeda®, a new sustained-release 
morphine formulation combined with naltrexone as an abuse 
deterrent.
MSContin twice a day
MSContin (Purdue Pharma, Stamford, CT) was the first 
of the controlled-release tablet forms of morphine sulfate 
developed. The morphine sulfate in MSContin is contained 
in a dual-action polymer mix consisting of a hydrophilic 
polymer (hydroxypropyl methylcellulose) and a hydropho-
bic polymer (hydroxyethyl cellulose), cetostearyl alcohol, 
hypromellose, magnesium stearate, polyethylene glycol, 
talc, and titanium dioxide.25 During preparation of the 
system, the drug is blended with the hydrophilic polymer, 
selectively hydrated with a polar solvent, and fixed with 
a higher aliphatic alcohol.26 The partition coefficients of 
the active ingredient with the hydrophilic and hydrophobic 
components of the formulation control the release of drug 
from the tablet.27 The hydrophobic content is used to slow 
the diffusion of drug into the aqueous phase, which limits 
diffusion into the GI tract and absorption into the body.28 
In other words, following administration, the gastric fluid 
dissolves the tablet surface and hydrates the hydrophilic 
polymer to produce a gel, the formation of which is con-
trolled by the higher aliphatic alcohols. The rate of drug 
release from this formulation depends on the rate of diffu-
sion of the dissolved morphine through the gel layer at the 
surface of the tablet. The depth of the gel layer increases 
over time as the gastric fluid gains access to the deeper 
regions of the tablet. The release rate can be controlled by 
varying the hydrophilic polymer, the type of hydrophobic 
matrix, or their ratio.29 MSContin is available as 15 mg, 
30 mg, 60 mg, 100 mg, and 200 mg tablets.
A suspension formula of MSContin is also available. 
In suspension, the morphine is attached to small beads of an 
ion exchange resin. Individual doses of the ion exchange resin 
are contained within a sachet, which must be reconstituted in 
water immediately before use to produce a suspension. Once 
administered, the sodium and potassium ions present in the GI 
tract fluid gradually displace morphine from the resin. Adding 
different amounts of the morphine-ion exchange resin complex 
to the sachet changes the dose delivered.29 Lastly, there is a 
controlled-release rectal formulation that contains morphine, 
sodium alginate, and a calcium salt in a vehicle that melts in 
the rectum. The calcium salt cross-links with sodium alginate 
to form a high viscosity complex, which controls the rate of 
morphine dissolution and release.29
Oramorph® twice a day
Oramorph® (Xanodyne Pharmaceuticals, Newport, KY) 
sustained-release tablets contain morphine sulfate in a 
simple matrix system. This allows for morphine sulfate to be 
prepared in tablet form rather than a capsule. The drug and 
any additional ingredients (colloidal silicon dioxide, lactose, 
and stearic acid) are uniformly blended with a hydrophilic 
polymer, typically hydroxypropyl methylcellulose, and then 
compressed into biconvex tablets.30 After ingestion, GI fluid 
enters the tablet and hydrates the hydrophilic hydroxypropyl 
methylcellulose matrix, causing it to swell and form a viscous 
gel layer. The gel layer controls both the diffusion of water 
into the system and the diffusion of the drug out of the system. 
Over time, this layer begins to breakdown and dissolve. Once 
this occurs, water penetrates deeper into the matrix, forming a 
new viscous gel layer. This process continues until the entire 
hydrophilic matrix is dissolved. The gel matrix effectively 
traps the active ingredient and slows its release, which may 
occur by diffusion through the gel layer or erosion of the gel 
matrix itself.28 The medication is available in 30 mg, 60 mg, 
and 100 mg tablets.
Kadian® once or twice a day
Kadian® (Alpharma Pharmaceuticals, Piscataway, NJ) or 
Kadian®, is a sustained-release formulation that places 
morphine sulfate in a capsule form by incorporating the 
drug into identical polymer-coated, sustained-release 
pellets contained in a hard gelatin capsule.31 The polymer 
coating consists of an insoluble ethylcellulose base along 
with polyethylene glycol and a methacrylic acid copolymer. 
Both the polyethylene glycol and the methacrylic acid 
copolymer are water-soluble, but the water solubility of 
the methacrylic acid copolymer is pH-dependent. After 
administration, the hard gelatin capsule shell quickly 
dissolves, releasing the drug-containing pellets. The acidity 
of the stomach causes the polyethylene glycol component 
of the polymer coating to start to dissolve, forming pores 
that allow GI fluid to enter the pellets and dissolve the 
morphine sulfate, which can then diffuse and be absorbed 
into the body. The pores are relatively small at this point, 
which limits drug diffusion. However, the dissolution of 
the polyethylene glycol component does allow for some 
drug to be absorbed quickly into the body (Figure 5). As the 
pellets enter and move through the intestines, the pH of the Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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GI environment continues to increase, and the methacrylic 
acid copolymer begins to dissolve as the polyethylene 
glycol continues its dissolution. This process increases the 
number and size of the pores in the polymer coating, which 
increases the rate of morphine release.28 The   medication is 
available in 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg 
100 mg, and 200 mg capsules, and can be administered 
once or twice a day.
Avinza® once a day
Avinza® (King Pharmaceuticals, Bristol, TN) or AvinzaA®, 
initially called Morphelan®, is an extended-release oral 
morphine formulation that differs from the previous 
extended-release morphine formulations in that it was 
designed for once-daily dosing. The formulation contains a 
mixture of immediate-release and extended-release beads, 
approximately 1–2 mm in diameter, which release morphine 
in a time-dependent manner.32 The immediate-release com-
ponent provides an initial rapid release of morphine, after 
which the extended-release component sustains therapeutic 
concentrations with minimal peak to trough fluctuation over 
a 24-hour dosing interval. The effect of the combination 
of these small beads, containing either immediate-release 
or extended-release morphine, is that plateau morphine 
concentrations can be achieved within 30 minutes, followed 
by maintenance of steady plasma concentrations throughout 
the 24-hour dosing interval.28,29 The extended-release beads 
are prepared using sugar/starch spheres upon which a drug/
excipient (“filler”) layer is coated, followed by an ammonio-
methacrylate copolymer coating. After administration and 
rapid dissolution of the hard gelatin capsule shell, the 
  permeability of the ammonio-methacrylate copolymer 
coating allows GI fluid to enter the beads and solubilize 
the drug. The entrance of GI fluid is mediated by fumaric 
acid, which acts as an osmotic agent and local pH modifier 
within the drug/excipient layer. As a result, drug release 
is independent of the pH of the surrounding GI environ-
ment. After dissolving, morphine then diffuses out of the 
beads at a predetermined rate. This process prolongs the 
dissolution of the drug and extends its absorption into the 
body. The immediate-release beads are formed by utiliz-
ing the same sugar/starch core and drug/excipient layer, 
without the rate-limiting polymer coating, and contains 
approximately 10% of the extended-release dose.33 One 
important caveat is that dosing is limited to 1600 mg per 
day or less due to fumaric acid-related renal toxicity.28 The 
medication is available in 30 mg, 45 mg, 60 mg, 75 mg, 90 
mg, and 120 mg capsules.
Embeda®
A novel morphine formulation intended to deter abuse, 
Embeda® (King Pharmaceuticals, Inc., Bristol, TN) or 
EmbedaA® has just been approved for use in the US. In an 
effort to create a reduced abuse formulation, Embeda® was 
designed as pellets of an extended-release morphine sulfate 
formulation surrounding an internal core of naltrexone 
hydrochloride (an opioid receptor antagonist) in a ratio of 
100:4 (morphine:naltrexone). The product is supplied as a 
gelatin capsule in dosages of 20 mg/0.8 mg, 30mg/1.2 mg, 
50 mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg, and 100 mg/4 mg 
(morphine sulfate/naltrexone hydrochloride).34 When 
these capsules are taken orally as directed, the naltrexone 
remains sequestered and should have no effect. However, 
chewing, pulverizing, or crushing the capsule or pellets 
would be expected to release the sequestered naltrexone, 
counter acting the effect of the morphine. Because of the 
pellet formulation, the capsules can be opened and sprinkled 
on apple sauce. One of the components of this drug is talc, 
so abusers who try to dissolve this pill for parenteral abuse 
may experience local tissue necrosis, infection, and other 
serious symptoms.34
Discussion
Once-or twice-daily extended-release morphine sulfate for 
the treatment of severe acute and chronic pain has many 
advantages over the use of the immediate-release formu-
lation. The most obvious is convenience, which leads to 
improved patient compliance. Arkinstall et al35 devised 
a randomized, double-blind crossover trial comparing 
twice-daily dosing of sustained-release morphine versus 
Polymer coating
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layer
Sugar/starch
sphere
Figure 5 Pellet sustained-release formulation.
Notes: Copyright © 2006, Harvey whitney Books Company. All rights reserved. 
Reproduced  with  permission  from  Amabile  CM,  Bowman  BJ.  Oral  modified-
release opioid products for chronic pain management. Ann Pharmacother. 2006;40 
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immediate-release morphine at four-hourly intervals, and 
found that there was no statistical difference between pain 
relief, pain scores, breakthrough pain, or the amount of res-
cue medication taken. However, the patients demonstrated 
a strong preference for the twice-daily dosing as opposed 
to the four-hourly dosing, for reasons of convenience and 
ease of use.
Similarly, in a study by Ferrell et al,36 patients with 
cancer pain who had been treated with immediate-release 
morphine formulations were randomly assigned to either 
switch to MSContin or continue on their immediate-release 
formulation. The patients who had been switched to MSCon-
tin reported a lower pain intensity, improved strength, 
improved quality of life and better adjustment to disease 
and treatment than did the patients on the immediate-release 
morphine.
Patient preference for convenience was also clearly dem-
onstrated in a study by Kerr and Tester37 in which patients 
taking Kadian® once daily reported pain scores and levels 
of interference with daily activities similar to those reported 
with MSContin twice daily, but there was a clear patient 
preference for Kadian® (55%) over MSContin (33%). Even 
though there was a statistically significant preference for 
once-daily dosing, there were no differences in pain control 
or tolerability between the two formulations. This suggests 
that the convenience of a once-daily versus twice-daily 
administration regimen may have been the cause of the clear 
patient preference for Kadian®. One possible explanation for 
this preference is that immediate-release morphine requires 
repeat dosing throughout the day, causing the patient to 
focus attention on pain and pain management, whereas the 
sustained-release morphine allows the patient to focus on 
other aspects of life throughout the day.38
Another advantage of the sustained-release morphine 
formulation is that it results in a more stable serum concen-
tration of the medication. With immediate-release morphine 
preparations, a steady state of serum morphine concentration 
is never obtained; the serum opioid levels rise rapidly follow-
ing administration and then decline rapidly, leading to poor 
pain control and decreased function. The sustained-release 
formulations allow for less fluctuation in serum opioid levels 
and prolong serum concentration levels within the therapeutic 
range.18 Studies comparing the effect of immediate-release 
morphine versus sustained-release morphine on pain control 
have shown a correlation between serum opioid concentra-
tion levels and pain control. This suggests that serum opioid 
concentrations are directly proportional to the level of anal-
gesia obtained.24,39
Currently, it is thought that measurable analgesia occurs 
when serum opioid concentrations exceed the minimum effec-
tive concentration and then analgesia falls once the serum 
concentration level is lower than the minimum effective 
concentration.29 Theoretically, sustained-release morphine 
formulations should maintain serum concentrations above 
the minimum effective concentration consistently, thereby 
providing more sustained pain relief without the need for 
repeated dosing.24 In fact, investigators have observed that 
in studies in which patients were taking modified-release 
opioids, the opioid daily dose remained stable over time.40 
This may suggest that reduction in trough-peak fluctuation by 
using sustained-release morphine as opposed to immediate-
release morphine may influence the development of tolerance 
by either preventing it from occurring or by reducing the pace 
at which it develops.
Confirming this theory with future studies would strongly 
reinforce the advantages of sustained-release morphine over 
immediate-release formulations. However, it is important 
to note that the trough-peak fluctuation has not been con-
firmed by controlled trials, nor have these fluctuations been 
compared between the short- and long-acting opioids; this 
currently should not be the reason for choosing one morphine 
formulation over another.
Nonetheless, differences in peak-trough fluctuations 
have even been noted between the different sustained-
release morphine formulations. In fact, in a study comparing 
Kadian®, Avinza®, and MSContin, Kadian® and Avinza® had 
smaller trough-peak fluctuations compared with MSContin.41 
  However, these pharmacokinetic differences have not cor-
related with improved efficacy or pain control.41,42
An important implication derived from the studies 
measuring the pharmacokinetic differences between the 
different sustained-release morphine formulations is that 
sustained-release morphine formulations do not appear to 
be   bioequivalent. A crossover study by Schobelock et al43 
reinforced this implication by measuring mean time to peak 
concentration, mean peak concentration, and the mean and 
minimum serum concentrations at steady state of Oramorph® 
and MSContin. Oramorph® or MSContin 30 mg was given 
every 12 hours for three days followed by a 14-day washout 
period before the alternative product was given. The mean time 
to peak concentration after Oramorph® was 3.75 ± 1.21 hours 
and after MSContin was 3.48 ± 1.25 hours. The mean peak 
concentration was 22.61 ± 5.83 ng/mL for Oramorph® and 
24.28 ± 5.28 ng/mL for MSContin. The mean and minimum 
serum concentrations were 11.06 ± 3.64 ng/mL for Oramorph® 
and 9.23 ± 2.94 ng/mg for MSContin. Although the t of these Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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two sustained-release morphine formulations were similar, 
they were by no means equivalent.
More recently, in an open-label study,44 32 patients with 
advanced cancer pain were randomized to receive   MSContin or 
Oramorph® every 12 hours around the clock for five days, with 
immediate-release liquid morphine for rescue   dosing. At the 
presumed morphine steady state (day 3), pain scores, as well 
as number and frequency of rescue doses, were   consistently 
greater in the MSContin group (despite a higher median mor-
phine dose in that group). There was a clinically important and 
directionally consistent trend that favored Oramorph®, although 
not all values were statistically significant, and patient prefer-
ence favored Oramorph® (P , 0.05). Patients did not have 
difficulty swallowing either   medication. The data suggested (but 
does not prove), by multiple clinically important measures, that 
Oramorph® may provide superior analgesic efficacy and less 
toxicity compared with MSContin. It also supports the concept 
that it cannot be assumed that different sustained-release for-
mulations of a given opioid are clinically equivalent.
It has been hypothesized that reducing the peak-trough 
fluctuation in serum opioid concentration may decrease 
the risk of adverse events and periods of inadequate pain 
control.24,28 Most patients develop tolerance to these side 
effects, except for constipation.24 Nonetheless, it is possible 
that reduced fluctuation in serum morphine levels might 
enhance the development of tolerance to some adverse 
side effects.28 One important caveat is that, of the potential 
side effects from morphine use, respiratory depression 
appears to be quite dose-dependent. Thus, once tolerance 
to the lesser side effects develops, a more consistent opioid 
serum concentration should be sought so as to decrease the 
chance of dose-related respiratory depression, which lends 
further support to the use of sustained-release morphine over 
immediate-release morphine, especially in the management 
of a chronic condition.24
Additionally, sustained-release morphine has also been 
linked to improvement in quality of life and sleep. A lon-
gitudinal study of nursing home residents found greater 
improvements in functional parameters and social engage-
ment when patients were treated with sustained-release 
morphine compared with immediate-release morphine.45 
Rosenthal et al46 found that patients taking sustained-release 
opioids had improved objective sleep measures recorded by 
polysomnography, including reduced latency to rapid eye 
movement sleep, increased time spent in Stage 2 sleep and 
rapid eye movement sleep, improved sleep continuity, and 
reduced sleep latency to persistent sleep.
According to the information noted above, it appears that 
sustained-release morphine would be superior to immediate-
release morphine in the treatment of severe acute and chronic 
pain. However, there are no definitive studies to confirm this 
assumption, especially given that there are no large, multi-
center, placebo-controlled   head-to-head   trials measuring the 
overall effectiveness of sustained-release morphine compared 
with immediate-release morphine   specifically for the treat-
ment of severe acute and chronic pain. In fact, it is important to 
note that one study found that there was no significant differ-
ence in pain scores between   immediate-release morphine and 
sustained-release morphine.39 Similarly, studies comparing 
short-acting and long-acting oxycodone and tramadol found 
no evidence that the long-acting formula was better than the 
short-acting formula in improving pain control.47–49
Furthermore, there is a clear disadvantage of the 
sustained-release formulations in that they are very sensitive 
to conditions that alter their modified-release mechanisms. 
Therefore, most of these products must be swallowed whole 
and never broken, chewed, crushed or dissolved, due to the 
risk of rapid opioid release and absorption of potentially 
fatal doses.   However, in patients with dysphagia, the entire 
capsule contents of Avinza®, Kadian®, or Embeda® can be 
sprinkled onto apple sauce immediately prior to administra-
tion. The prescribing information for Kadian® also indicates 
that the entire capsule contents may be administered through 
a 16 French gastrostomy tube.31
Sustained-release opioids should promote less addiction 
behavior by disconnecting the “pop-a-pill-feel-better” effect 
of immediate-release opioids, although this has never been 
proven. This risk of addiction is a serious national health issue; 
between 1992 and 2003, the US population increased by 14%, 
while the number of people abusing controlled prescription 
drugs increased by 94%, twice the increase in the number 
of people abusing marijuana, five times the number abusing 
cocaine, and 60 times the number abusing heroin.17
Embeda®, with its deterrent formulation, should also help 
decrease that risk; however, those studies have not yet been 
done. A pharmacodynamic study to evaluate the effect of 
naltrexone in the setting of crushed Embeda® used a random-
ized double-blind, triple-dummy, four-way crossover design 
to compare the effects of Embeda® whole and crushed with 
those of 120 mg of immediate-release morphine and placebo, 
in 32 nondependent recreational opioid users.34 Overall, 
87.5% of the subjects had some degree of reduced drug-
liking after receiving crushed Embeda®, while 12.5% had 
no reduction in drug-liking. There was a considerable range Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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in individual degrees of reduction in drug-liking, ranging 
between 10% and 50%. Similarly, 9% of the subjects showed 
some degree of decreased euphoria with crushed Embeda® 
compared with immediate-release morphine. Meanwhile, the 
naltrexone in Embeda® does not appear to decrease analgesia. 
A multicenter, 12-month efficacy study50 of 465 opioid-
tolerant patients with chronic moderate to severe noncancer 
pain showed that more than 90% of the patients completing 
the study (162 of the original 465 patients) reported good-to-
excellent global assessment of their pain relief. Most common 
adverse events were constipation (31.8%), nausea (25.2%), 
headache (12.0%), and vomiting (11.8%).
Conclusion
The American Pain Society22 states that the choice of opi-
oid is based on the clinician’s experience with an agent, 
because there are limited data supporting any preferred 
agent. Clinicians also base their choice of opioid on any 
patient’s previous experience, given that some patients will 
tolerate or respond to particular agents better than others. 
An extended-release analgesic should provide around-the-
clock efficacy, result in fewer changes in drug plasma con-
centrations when compared with short-acting analgesics, 
provide maximal tolerability, and have minimal long-term 
adverse events with prolonged use.22 Currently, there are 
no overwhelming data supporting superior efficacy of any 
one of the once- or twice-daily dose, oral modified-release, 
or immediate-acting opioid products.28 However, the 
pharmacologic and pharmacodynamic properties of these 
formulations provide more convenient dosing intervals for 
patients and can achieve stable and sustained blood con-
centrations, theoretically leading to improved pain control 
when compared with the immediate-release formulations 
in the treatment of severe acute and chronic pain.
There is also no evidence that extended-release formu-
lations decrease the risk of addiction, although the lack of 
rapid release and therefore lower overall blood levels is felt 
to disconnect the “pop-a-pill-feel-better” response of rapid-
onset medications. Until we have more studies, one must rely 
on sound clinical judgment and a risk/benefit assessment 
before initiating opioid treatment, while taking into account 
the current body of literature pertaining to this issue, the type 
of pain being treating, and the individuality of the patient.
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